Thu, Sep 18, 2014, 9:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

  • jesse164@ymail.com jesse164 Apr 2, 2013 9:34 AM Flag

    Thomson Reuters Upgardes OPK to 10

    OPKO HEALTH INCORPORATION (OPK-N)
    Pharma. & Med. Research / Pharmaceuticals / Pharmaceuticals
    Indicator Description
    The
    Average Score
    combines the quantitative
    analysis of six widely-used investment decision
    making tools: Earnings, Fundamental, Relative
    Valuation, Risk, Price Momentum and Insider
    Trading. A simple average of the underlying
    component ratings is normally distributed to rank
    stocks on a 1-10 scale (10 being awarded to the
    highest scored). These factors may be evaluated
    differently using alternative methodologies and the
    importance of individual factors varies across
    industries, market capitalization and investment
    styles. Additional criteria should always by used to
    evaluate a stock.
    Indicator
    OPK is currently among an exclusive
    group of 221 stocks awarded our
    highest
    average
    score of 10.
    AVERAGE
    SCORE
    Peers
    INFI
    7
    THRX
    3
    ZTS
    NR
    TARO
    NR
    Averages
    Pharmaceuticals Group
    4.1
    Pharma. & Med. Research Sector
    4
    S&P 500 Index
    6.6
    Mid Market Cap
    6
    Indicator Trend
    Positive
    Neutral
    Negative
    1 Y
    Ago
    6 M
    Ago
    3 M
    Ago
    1 M
    Ago
    2 W
    Ago
    Current
    4
    3
    6
    6
    6
    10
    Last 5 Years
    Best
    Worst
    Average
    9
    - (01/22/12)
    3
    - (09/30/12)
    5.9
    Analyst Recommendations
    First Call Mean (FC):
    Strong Buy
    (3 firms)
    First Call Mean is the mean of all analysts covering the company.
    Sell
    Reduce
    Hold
    Buy
    Strong
    Buy
    FC
    Key Information
    Price (03/28/13) (USD)
    7.63
    52-Week High (USD)
    7.83
    52-Week Low (USD)
    4.00
    Market Cap (USD)
    2.5B
    Avg Daily Vol
    1.9M
    Exchange
    NEW YORK
    Annual Dividend (USD)
    --
    Trailing PE
    --
    Exp Report Date
    05/09/13
    Annual Revenue (USD)
    47M
    ROE
    -17.1%
    Inst. Ownership
    65.9%
    1-Mo Return
    9.9%
    3-Mo Return
    61.3%
    1-Yr Return
    61.3%
    Price Charts
    1-Year
    5-Year
    Business Description
    OPKO Health, Inc. (OPKO), incorporated in October 1991, is a multi-national pharmaceutical and
    diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent
    various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals
    and vaccines. Its pharmaceutical segment consists of two operating segments: pharmaceutical
    research and development segment which is focused on the research and development of
    pharmaceutical products, diagnostic tests and vaccines, and the pharmaceutical operations, which
    it acquired in Chile, Mexico and Israel. In August 2012, it acquired Farmadiet Group Holding, S.L. In
    December 2012, the Company acquired Prost-Data, Inc. In February 2013, the Company acquired
    Silcon Comercio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltda. In
    March 2013, the Company announced that it has completed the acquisition of Cytochroma Inc.
    Page 1 of 11
    © 2013 Thomson Reuters. All rights reserved.
    Detailed Stock Report
    Updated April 1, 2013
    Average Score
    AVERAGE
    SCORE
    The
    Average Score
    combines the quantitative analysis of six widely-used investment decision making tools:
    Earnings, Fundamental, Relative Valuation, Risk, Price Momentum and Insider Trading. A simple average of the
    underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the
    highest scored). These factors may be evaluated differently using alternative methodologies and the importance
    of individual factors varies across industries, market capitalization and investment styles. Additional criteria
    should always by used to evaluate a stock.
    Indicator Components
    Positive
    Neutral
    Negative
    No Rating
    Details
    Earnings
    See Page 3
    Fundamental
    See Page 5
    Relative
    Valuation
    See Page 6
    Risk
    See Page 8
    Price
    Momentum
    See Page 9
    Insider
    Trading
    See Page 10
    Optimized Score
    OPTIMIZED
    SCORE
    Historically, companies with an
    optimized score of 9 have tended to
    significantly outperform the market
    over the following 12-month period.
    As an alternative approach to equally weighting each of the six factors,
    independent research firm, Verus Analytics, conducted a backtest to empirically
    determine the optimal factor blend. Results and weighting vary across four
    different market capitalization categories. For large cap stocks, price momentum
    and insider trading historically provided the most explanatory power among the
    six factors and are weighted heavily in the current optimized score. Among the
    small cap universe, the earnings and fundamental factors joined with insider
    trading and price momentum to explain returns.
    Peer Analysis
    Ticker
    Average
    Score
    Market
    Cap
    (USD)
    Price
    (03/28/13)
    (USD)
    Dividend
    Yield
    Trailing
    PE
    Forward
    PE
    Forward
    PEG
    LTG
    Forecast
    Annual
    Revenue
    (USD)
    Net
    Margin
    1-Mo
    Return
    3-Mo
    Return
    1-Yr
    Return
    JAZZ
    7
    3.2B
    55.91
    --
    11.8
    9.6
    0.4
    27.3%
    476M
    18.8%
    -3.9%
    6.0%
    17.0%
    SLXP
    8
    3.1B
    51.18
    --
    50.7
    15.1
    0.7
    20.8%
    692M
    8.9%
    4.8%
    28.9%
    -2.9%
    CBST
    8
    3.0B
    46.82
    --
    22.4
    32.9
    0.9
    34.7%
    926M
    15.4%
    10.3%
    12.5%
    6.9%
    ZTS
    --
    2.9B
    33.40
    --
    --
    25.5
    2.3
    11.0%
    4.3B
    15.8%
    -0.1%
    --
    --
    TARO
    --
    2.6B
    58.69
    --
    --
    --
    --
    --
    521M
    47.8%
    2.9%
    21.9%
    50.5%
    OPK
    10
    2.5B
    7.63
    --
    --
    --
    --
    --
    47M
    -6.5%
    9.9%
    61.3%
    61.3%
    THRX
    3
    2.3B
    23.62
    --
    --
    --
    --
    --
    136M
    -540.1%
    16.4%
    11.0%
    18.6%
    INFI
    7
    2.3B
    48.47
    --
    --
    --
    --
    --
    69M
    -66.9%
    17.4%
    39.6%
    301.6%
    QCOR
    5
    1.9B
    32.54
    3.1%
    10.3
    7.5
    0.3
    28.0%
    424M
    39.7%
    -0.2%
    20.8%
    -14.7%
    MDCO
    6
    1.8B
    33.41
    --
    35.5
    35.8
    0.7
    48.7%
    559M
    13.0%
    5.0%
    40.6%
    65.7%
    MWIV
    6
    1.7B
    132.26
    --
    29.4
    26.4
    1.8
    15.0%
    2.2B
    2.9%
    4.8%
    21.4%
    52.9%
    Average
    6.7
    2.5B
    --
    3.1%
    26.7
    21.8
    1.0
    26.5%
    939M
    -41.0%
    6.1%
    26.4%
    55.7%
    Median
    7.0
    2.5B
    --
    3.1%
    25.9
    25.5
    0.7
    27.3%
    521M
    13.0%
    4.8%
    21.6%
    34.6%
    Peer Group
    JAZZ
    JAZZ PHA
    THRX
    THERAVANCE INC
    SLXP
    SALIX PHARMACEUTICAL
    INFI
    INFINITY PHARMA
    CBST
    CUBIST PHARMACEUTICALS
    QCOR
    QUESTCOR PHARM.
    ZTS
    ZOETIS
    MDCO
    MEDICINES COMPANY
    TARO
    TARO PHARMA
    MWIV
    MWI VETERINARY
    Page 2 of 11
    © 2013 Thomson Reuters. All rights reserved.
    Detailed Stock Report
    Updated April 1, 2013 for OPK-N

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OPK
8.48-0.06(-0.70%)Sep 18 4:04 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.